Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Can Do Ramadan Study
ISRCTN14964201Phase 4Completed
- Sponsor
- University of Leicester
- Start
- Aug 2016
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of canagliflozin, metformin, repaglinide and pioglitazone in type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by University of Leicester. Primary endpoint: Double composite endpoint of HbA1c reduction and weight loss. Started Aug 2016; status: completed.
02
Drugs
canagliflozinmetforminrepaglinidepioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN14964201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14964201.